SCHEMBL2744652

SCHEMBL2744652

COc1cc(Br)cc(/C=C/C(=O)/C=C/c2cc(Br)cc(OC)c2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F3 P13726 1/20 0.56
CYP1A2 P05177 5/20 0.53
CYP2D6 P10635 5/20 0.53
CYP3A4 P08684 2/20 0.53
CYP2C9 P11712 2/20 0.53
CYP2B6 P20813 2/20 0.53
BACE1 P56817 2/20 0.53
HSD17B3 P37058 1/20 0.50
CYP1A1 P04798 3/20 0.48
CYP1B1 Q16678 2/20 0.48
JUN P05412 2/20 0.48
FOS P01100 1/20 0.48
ABCG2 Q9UNQ0 3/20 0.47
NFKB1 P19838 3/20 0.46
STAT3 P40763 3/20 0.46
ALOX5 P09917 2/20 0.46
NFKB2 Q00653 2/20 0.46
RELA Q04206 2/20 0.46
NFE2L2 Q16236 2/20 0.46
MAOA P21397 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2744655 1.00 F3 (0.56) F3CYP1A2CYP2D6CYP3A4CYP2C9
SCHEMBL3017301 0.88 THRB (0.57) CYP1A2CYP2D6BACE1CYP1A1CYP1B1
SCHEMBL3017298 0.88 THRB (0.57) CYP1A2CYP2D6BACE1CYP1A1CYP1B1
SCHEMBL5598963 0.87 F3 (0.66) F3CYP1A2CYP2D6CYP3A4CYP2C9
SCHEMBL5598966 0.87 F3 (0.66) F3CYP1A2CYP2D6CYP3A4CYP2C9
SCHEMBL21835129 0.87 BACE1 (0.54) CYP1A2CYP2D6BACE1CYP1A1CYP1B1
SCHEMBL16307036 0.87 BACE1 (0.54) CYP1A2CYP2D6BACE1CYP1A1CYP1B1
SCHEMBL29937522 0.87 BACE1 (0.54) CYP1A2CYP2D6BACE1CYP1A1CYP1B1
SCHEMBL29606654 0.85 F3 (0.63) F3CYP1A2CYP2D6CYP3A4CYP2C9
SCHEMBL22837938 0.82 MAOB (0.52) CYP1A2CYP3A4CYP2C9BACE1ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178727-B2 Bis(arylmethylidene)acetone compound, anti-cancer agent, carcinogenesis-preventive agent, inhibitor of expression of Ki-Ras, ErbB2, c-Myc and Cycline D1, β-catenin-degrading agent, and p53 expression enhancer NATIONAL UNIVERSITY CORPORATION TOHOKU UNIVERSITY (JP) 2012-05-15 US disclosed
US-20100152493-A1 BIS(ARYLMETHYLIDENE)ACETONE COMPOUND, ANTI-CANCER AGENT, CARCINOGENESIS-PREVENTIVE AGENT, INHIBITOR OF EXPRESSION OF Ki-Ras, ErbB2, c-Myc AND CYCLINE D1, BETA-CATENIN-DEGRADING AGENT, AND p53 EXPRESSION ENHANCER SHIBATA, HIROYUKI (JP) 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152493-A1 BIS(ARYLMETHYLIDENE)ACETONE COMPOUND, ANTI-CANCER AGENT, CARCINOGENESIS-PREVENTIVE AGENT, INHIBITOR OF EXPRESSION OF Ki-Ras, ErbB2, c-Myc AND CYCLINE D1, BETA-CATENIN-DEGRADING AGENT, AND p53 EXPRESSION ENHANCER MYC, CCNE2, CCNE1 F3 3373/4885CYP1A2 1717/4885CYP2D6 1871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.